Vaxcyte (PCVX) Competitors $31.56 +0.77 (+2.50%) Closing price 04:00 PM EasternExtended Trading$31.56 0.00 (-0.02%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. GMAB, VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIVShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Vaxcyte (NASDAQ:PCVX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Do institutionals & insiders believe in PCVX or GMAB? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is PCVX or GMAB more profitable? Genmab A/S has a net margin of 37.53% compared to Vaxcyte's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -16.85% -15.92% Genmab A/S 37.53%21.03%16.98% Does the media refer more to PCVX or GMAB? In the previous week, Genmab A/S had 1 more articles in the media than Vaxcyte. MarketBeat recorded 11 mentions for Genmab A/S and 10 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.55 beat Genmab A/S's score of 1.22 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Genmab A/S 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, PCVX or GMAB? Genmab A/S has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$4.11-7.68Genmab A/S$3.12B5.32$1.14B$1.9913.01 Which has more risk and volatility, PCVX or GMAB? Vaxcyte has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do analysts recommend PCVX or GMAB? Vaxcyte presently has a consensus price target of $136.50, indicating a potential upside of 332.51%. Genmab A/S has a consensus price target of $37.60, indicating a potential upside of 45.23%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64 SummaryGenmab A/S beats Vaxcyte on 8 of the 15 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.10B$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-7.6820.9982.6526.40Price / SalesN/A396.26529.10204.59Price / CashN/A43.5325.7028.92Price / Book1.199.8811.246.06Net Income-$463.93M-$53.38M$3.28B$266.05M7 Day Performance4.33%-0.14%0.15%-0.07%1 Month Performance-4.42%9.18%8.36%5.83%1 Year Performance-60.92%7.53%54.25%17.89% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte2.6644 of 5 stars$31.56+2.5%$136.50+332.5%-61.9%$4.10BN/A-7.68160News CoveragePositive NewsGMABGenmab A/S3.9211 of 5 stars$24.87-1.0%$37.60+51.2%-10.5%$15.96B$3.26B12.502,682Positive NewsGap UpVTRSViatris1.8394 of 5 stars$10.55+1.3%$10.40-1.4%-12.7%$12.30B$14.12B-3.6432,000ASNDAscendis Pharma A/S3.3642 of 5 stars$194.27+0.2%$243.36+25.3%+40.3%$11.89B$393.54M-37.651,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.6452 of 5 stars$14.20-0.1%$16.95+19.4%-15.0%$11.85B$3.81B21.5127,811News CoveragePositive NewsQGENQiagen4.1205 of 5 stars$46.53+0.9%$49.69+6.8%+4.7%$10.34B$2.04B27.495,765News CoveragePositive NewsBBIOBridgeBio Pharma4.057 of 5 stars$51.76-1.5%$62.18+20.1%+85.9%$9.89B$235.81M-12.66400Positive NewsMRNAModerna4.5273 of 5 stars$24.09-1.6%$42.88+78.0%-68.9%$9.37B$3.06B-3.205,800ELANElanco Animal Health2.7834 of 5 stars$18.38-0.4%$17.33-5.7%+18.8%$9.13B$4.48B21.379,000High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.2385 of 5 stars$105.91+0.0%$109.00+2.9%+285.4%$8.67B$221.67M-106.9830News CoveragePositive NewsROIVRoivant Sciences3.0692 of 5 stars$11.93-0.1%$16.50+38.3%-2.5%$8.15B$29.05M-17.04860News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Genmab A/S Competitors Viatris Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Qiagen Competitors BridgeBio Pharma Competitors Moderna Competitors Elanco Animal Health Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
